PTC Inc. (PTC) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.20 per share a year ago.
Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design and testing software as companies keep a tight leash on budgets.
PTC's fiscal fourth-quarter performance is likely to have been driven by strong business momentum across PLM and CAD segments amid forex fluctuations.
Evaluate the expected performance of PTC Inc. (PTC) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Inc. PTC has inked a Strategic Collaboration Agreement with Amazon Web Services (“AWS”) to boost the growth of its Onshape solution. This collaboration aims to enhance Onshape's capabilities, promote customer adoption and advance AI initiatives, all intended to help designers and engineers create high-quality products more swiftly and efficiently.
Roblox is posting very strong growth, but its stock still trades far below its previous high. Despite challenging end-market trends, software company PTC keeps generating double-digit growth in its key metric.
PTC Therapeutics, Inc. achieved dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients, using 5 mg and 10 mg of PTC518. The global Huntington's Disease treatment market is expected to reach $3.06 billion by 2033. NDA of sepiapterin for the treatment of patients with phenylketonuria submitted July 2024.
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The annual run rate of recurring revenue continues to grow at a double-digit rate. Free cash flow is growing more than recurring revenue growth.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.